{"schema_version":"secwatch.filing_event.v1","accession":"0001867096-25-000085","form_type":"8-K","ticker":"XERS","cik":"0001867096","company_name":"Xeris Biopharma Holdings, Inc.","filed_at":"2025-05-08T23:59:59+00:00","discovered_at":"2026-05-14T18:02:50.288570+00:00","generated_at":"2026-05-22T05:35:43.718666+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Xeris Q1 revenue up 48% to $60.1M; Recorlev surges 141%; tightens FY guidance to $260-275M","bullets":["Total revenue $60.1M (+48% YoY); net loss $9.2M ($0.06 loss per share) vs prior year loss.","Recorlev revenue $25.5M (+141%); Gvoke $20.8M (+26%); Keveyis $11.4M (-13%).","Adjusted EBITDA positive $4.4M, an improvement of $8.4M vs Q1 2024.","FY 2025 total revenue guidance tightened to $260M-$275M from $255M-$275M.","Announces Analyst & Investor Day on June 3, 2025 in NYC to discuss Recorlev and XP-8121."],"urls":{"canonical":"https://secwatch.observer/filing/0001867096-25-000085","json":"https://secwatch.observer/filing/0001867096-25-000085.json","markdown":"https://secwatch.observer/filing/0001867096-25-000085.md","text":"https://secwatch.observer/filing/0001867096-25-000085.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1867096/000186709625000085/0001867096-25-000085-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1867096/000186709625000085/xers-20250508.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-22T05:35:43.718666+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}